Publication | Closed Access

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Gene TherapiesClinical TrialsNeurologyMedicinePhase 3